hologic stock: HOLX Overview & Facts

Hologic (HOLX) (Overview)

Hologic stock (HOLX) refers to shares of Hologic, Inc., a U.S.-based medical technology company listed on the NASDAQ. This article explains what hologic stock represents, summarizes the company’s business in women’s health and diagnostics, and reviews recent financial results and corporate events to help investors and researchers find authoritative resources and next steps. As of 2026-01-29, according to StockStory, Hologic reported last-quarter revenue of $1.05 billion, beating analysts’ expectations by 1.5%.

Company background

Hologic, Inc. was founded in 1985 and has since grown into a diversified medical technology company focused primarily on women’s health. The company’s mission centers on improving patient health through screening, diagnostics, image-guided therapies and surgical products. Over several decades Hologic expanded from cytology and screening technologies into molecular diagnostics, breast-imaging platforms and minimally invasive surgical devices.

Major historical milestones that shaped the business include the development and commercialization of cytology and screening platforms, acquisitions that broadened diagnostic and imaging capabilities, and steady investments in molecular assay development and automated laboratory systems. Notable corporate moves and acquisitions have helped Hologic build a portfolio spanning diagnostic assays, breast health imaging, gynecological surgical devices and skeletal health measurement technologies.

Business segments and products

Hologic reports its operations across principal segments aligned with its product families. The following summary outlines those segments and key technologies that define Hologic’s market offering:

• Diagnostics

  • Molecular assays and automation platforms for infectious disease and women’s health testing. Notable platforms include the Panther system and Aptima molecular assays.
  • Diagnostic product lines include nucleic acid amplification assays and integrated workflows for clinical laboratories.

• Breast Health

  • Imaging technologies and related consumables, including ThinPrep cytology, 2D/3D mammography systems, and advanced tomosynthesis platforms.
  • Hologic’s 3D mammography platforms and related analytics aim to improve detection while managing workflow and radiation dose.

• GYN Surgical

  • Minimally invasive surgical products for gynecologic procedures, including devices for endometrial ablation, tissue removal and procedural systems such as MyoSure and NovaSure.

• Skeletal Health

  • Bone densitometry and related diagnostic tools such as Horizon DXA and Fluoroscan systems for skeletal assessment and procedural imaging.

Each segment couples instruments with consumables, software and services. Hologic emphasizes installed base advantages (recurring consumable sales and service revenue) plus proprietary assays and imaging algorithms to differentiate its offerings.

Market position and competition

Hologic holds a specialized position within women’s health, diagnostics and select imaging niches. Its market strengths include:

• A broad installed base across imaging and diagnostic platforms that drives recurring consumables and service revenue.
• Proprietary assays (e.g., Aptima) and integrated laboratory automation (e.g., Panther) that serve clinical and reference labs.
• Imaging technology with a focus on breast health and tomosynthesis, paired with analytic tools to support detection and workflow.

Primary competitors vary by segment. In diagnostics and assays, competitors include large medtech and life-sciences companies that supply instruments and assays to clinical labs. In imaging, Hologic competes with medical imaging divisions of large diversified manufacturers. In gynecologic surgical devices, competition comes from specialized surgical device makers. Competition drivers include clinical performance, installed base relationships, regulatory approvals, pricing, and sales/service coverage.

Addressable markets include breast imaging, clinical molecular diagnostics, gynecologic surgical devices and skeletal health measurement — each with distinct growth dynamics influenced by screening guidelines, demographic trends, and laboratory testing demand.

Financials and stock information

This section summarizes public-equity facts about hologic stock (HOLX). Financial indicators change frequently; readers should confirm live metrics on official investor pages and financial data providers.

• Ticker and exchange: Hologic trades under the ticker HOLX on the NASDAQ.
• Recent revenue context: As of 2026-01-29, Hologic reported last-quarter revenue of $1.05 billion, up 6.2% year-over-year and beating analysts’ revenue expectations by 1.5% (source: StockStory).
• Near-term revenue expectations: For the upcoming quarter analysts were modeling revenue of approximately $1.07 billion (a 4.8% year-over-year increase) and adjusted earnings of about $1.10 per share (source: StockStory, as of 2026-01-29).

Note: market capitalization, P/E ratio, earnings per share and daily trading volume fluctuate intraday. Use authoritative sources such as the company’s investor relations site and major financial platforms (listed in the References) for live values and time-stamped snapshots.

Historical stock performance

Hologic stock has experienced multi-year moves driven by product cycles, diagnostic demand, macro health-care sector trends and discrete corporate events. Key points on historical performance:

• Price swings typically align with quarterly earnings, guidance revisions, and regulatory or M&A news.
• Over the trailing 52-week window prior to 2026-01-29 the share price showed volatility consistent with peers in the healthcare equipment and supplies segment, with analysts’ average price target reported at $76.92 compared to a then-current share price of $75.20 (source: StockStory).
• Hologic has historically shown the ability to beat top-line estimates more often than not; StockStory notes the company missed revenue estimates only once in the prior two years and exceeded top-line expectations by an average of about 1.2%.

Exact historical return metrics, 52-week range and multi-year charts should be referenced on live quote pages for precision.

Analyst coverage and ratings

Major sell-side and independent research providers cover Hologic. Analyst opinions frequently appear as buy/hold/sell ratings and price targets on financial platforms. As of 2026-01-29:

• The average analyst price target reported by StockStory was $76.92 (source: StockStory).
• Over the 30-day run-up to the most recent earnings period, analysts generally reconfirmed estimates, suggesting broad stability in near-term outlooks (source: StockStory).

Analyst coverage may include revisions around earnings releases, product approvals or material corporate events. For the most recent and authoritative analyst reports consult professional subscription services or the analyst coverage tab on public financial portals.

Major corporate events and recent developments

Hologic’s share value can be materially affected by corporate actions, regulatory approvals and M&A. Two categories are notable in recent years:

• Earnings and operating updates

  • As of 2026-01-29, Hologic reported last-quarter revenues of $1.05 billion (up 6.2% y/y) and beat consensus by roughly 1.5%. Analysts expected the upcoming quarter to show revenue of about $1.07 billion and adjusted EPS near $1.10 (source: StockStory). Historically, Hologic has outperformed revenue estimates more often than not.

• M&A and strategic transactions

  • On October 21, 2025, Hologic announced a definitive agreement to be acquired by a buyer group led by Blackstone and TPG. Under the terms disclosed in that press release, the transaction offered up to $79.00 per share in total consideration — consisting of $76.00 in cash and a contingent value right (CVR) of up to $3.00 tied to certain milestones (source: Hologic press release, Oct 21, 2025). This transaction, when completed, would be a significant corporate event with direct implications for Hologic stock holders and public float.

Material events like a definitive acquisition agreement may result in trading halts, tender offer periods, shareholder votes and regulatory clearances. Investors should review the company press release and SEC filings for transaction details and timeline.

Governance and management

Hologic’s governance framework comprises a board of directors and an executive leadership team responsible for corporate strategy and operations. Typical governance materials include:

• Board composition and committee charters (audit, compensation, nominations)
• Executive officers such as the Chief Executive Officer and Chief Financial Officer (names and roles change over time; verify current incumbents on investor relations pages)
• Executive compensation disclosures and shareholder communications

For the most recent board roster, executive biographies and governance documents, consult Hologic’s investor relations materials and proxy statements, which provide time-stamped details of directors, committee assignments and governance policies.

Regulatory, legal and compliance matters

Hologic operates in heavily regulated markets. Regulatory approvals, compliance with medical device and diagnostics regulations, and legal proceedings can materially affect business operations and the stock.

• Regulatory approvals: Product launches and geographic expansions depend on clearances or approvals from relevant regulatory bodies.
• Legal proceedings: Hologic periodically discloses material litigation, regulatory inquiries or product-related claims in SEC filings. Such items can include patent suits, product liability claims or contractual disputes.

Investors and researchers should review the company’s filings and press releases for time-stamped disclosures of any material legal or regulatory matters. This ensures an accurate assessment of potential exposures.

Research, development and innovation

Hologic invests in R&D across diagnostics, imaging, surgical devices and related software. R&D focus areas typically include:

• Molecular diagnostics and assay development (e.g., expanding catalog of Aptima assays)
• Automation and throughput improvements for laboratory workflows (e.g., Panther platform enhancements)
• Imaging improvements (image quality, tomosynthesis algorithms) and software analytics to support clinical decision making
• Minimally invasive surgical tools and procedural efficiencies

Partnerships with academic centers, clinical labs and technology partners often support product validation and commercialization. Pipeline updates, R&D spending and clinical trial outcomes are disclosed in earnings materials and regulatory filings.

Environmental, social and governance (ESG)

Hologic publishes sustainability and ESG disclosures that cover topics such as product stewardship, employee health and safety, diversity and inclusion, and environmental initiatives. ESG summaries typically highlight:

• Sustainability goals and progress indicators
• Workplace and diversity policies
• Product and clinical impact on public health (particularly in women’s health access and screening programs)

For specific metrics, index inclusions or third-party recognitions, consult the company’s published sustainability reports and official ESG disclosures.

Investor information

Where to find authoritative and time-stamped investor information for hologic stock (HOLX):

• Hologic Investor Relations: primary source for SEC filings, press releases, earnings presentations, and governance documents.
• Company press releases: use for transaction notices (for example, the Oct 21, 2025 announcement of the Blackstone/TPG transaction).
• Financial quote and data platforms (e.g., Yahoo Finance, MarketWatch, Morningstar, CNBC, Robinhood): use for live quotes, analyst consensus, historical charts and trading volumes. Verify the time-stamp on any metric you rely on.

Earnings and investor events:

• Hologic generally posts an earnings schedule and materials on the investor relations page. As of 2026-01-29, Hologic was scheduled to report earnings after market hours on a Thursday (source: StockStory).

Trading and execution:

• If you are looking to trade equities, note that Hologic trades on the NASDAQ under HOLX. When considering an execution venue, consider using Bitget for market access and wallet services consistent with your preferences (platform availability, supported products and regional rules vary).

See also

• Women’s health diagnostics
• Molecular diagnostics and lab automation
• Breast imaging technologies and tomosynthesis
• Comparable public companies in healthcare equipment and supplies

References

• Hologic press release — Acquisition by Blackstone and TPG (Oct 21, 2025)
• Hologic Investor Relations — Stock Info and filings (accessed 2026-01-29)
• StockStory — Hologic earnings preview and analysis (accessed 2026-01-29)
• Yahoo Finance — Hologic, Inc. (HOLX) page (accessed 2026-01-29)
• MarketWatch — HOLX stock price and profile (accessed 2026-01-29)
• Morningstar — Hologic quote and analysis (accessed 2026-01-29)
• CNBC — HOLX stock quote (accessed 2026-01-29)
• Robinhood — Hologic: HOLX stock quote & news (accessed 2026-01-29)

(Readers should consult these sources directly for live figures and the most recent company disclosures.)

External links

• Hologic official website
• Hologic investor relations page
• Real-time quote pages on major financial platforms (Yahoo Finance, MarketWatch, Morningstar, CNBC)

Further exploration and next steps

If you want a printable investor checklist for hologic stock (HOLX) — covering items such as latest SEC filings, recent earnings presentation, scheduled shareholder votes related to the 2025 transaction, and analyst note links — say the word and I will prepare a time-stamped checklist and a short monitoring template you can use with Bitget alerts and watchlists.